Investors sold shares of Merck & Company, Inc. (NYSE:MRK) on strength during trading on Wednesday. $67.79 million flowed into the stock on the tick-up and $86.52 million flowed out of the stock on the tick-down, for a money net flow of $18.73 million out of the stock. Of all equities tracked, Merck & had the 23rd highest net out-flow for the day. Merck & traded up $0.10 for the day and closed at $54.37

Several research firms have issued reports on MRK. Cowen and Company restated a “hold” rating and issued a $70.00 price target on shares of Merck & in a research report on Friday, November 3rd. J P Morgan Chase & Co set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a research report on Sunday, October 29th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC restated a “sell” rating and issued a $55.00 price target on shares of Merck & in a research report on Friday, October 20th. Finally, Barclays PLC lowered shares of Merck & from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $72.00 to $62.00 in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.87.

The stock has a market cap of $148,290.00, a price-to-earnings ratio of 13.91, a PEG ratio of 2.33 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The firm had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period last year, the firm posted $1.07 EPS. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. equities research analysts predict that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

In related news, Director Thomas H. Glocer sold 5,000 shares of Merck & stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.25% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Fort Washington Investment Advisors Inc. OH lifted its holdings in Merck & by 133.4% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock valued at $9,165,000 after purchasing an additional 82,454 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Merck & by 2.6% in the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after acquiring an additional 107,201 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its stake in shares of Merck & by 41.9% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after acquiring an additional 87,443 shares during the last quarter. Stevens Capital Management LP bought a new position in shares of Merck & in the first quarter worth about $15,126,000. Finally, Trust Co raised its stake in shares of Merck & by 2.8% in the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after acquiring an additional 1,852 shares during the last quarter. 72.98% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/22/traders-sell-merck-company-inc-mrk-on-strength-mrk.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.